Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
Lucid Diagnostics reported Q2 2026 revenue of $1.5 million, processing 2,770 EsoGuard tests during the quarter. The company secured its first laboratory benefit manager coverage policy from Concert, designating EsoGuard as medically necessary for eligible patients.
Key figures
- Revenue
- 1474000
- Cash
- 33400000
- Net loss
- 14700000
- Adjusted loss
- 10900000
- Tests processed
- 2770
- Operating expenses
- 14300000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.